Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK in sickle cell, thalassaemia screening drive:

This article was originally published in Clinica

Executive Summary

The UK NHS will launch sickle cell and thalassaemia screening programmes in July. Sickle cell affects some 1 in 2,400 births - around 300 a year in England. There are an estimated 12,500 cases with this serious blood disorder. The prevalence on thalassaemia is lower (at around 700 in England), but there has been a 45% combined increase in the two diseases between 1991 and 2001, says the NHS Sickle Cell and Thalassaemia Programme. Testing for thalassaemia will be performed as part of the programme for phenylketonuria and congenital hypothyroidism, in the form of a "heel-prick" or dried bloodspot test. Both programmes are being launched in Birmingham, and are aimed particularly at the communities with higher risk of the disease. They are due to be fully rolled out by March 2006.

You may also be interested in...

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

FDA Wants To Put Hep C Tests On 510(k) Pathway

The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts